Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Monday . Approximately 5,632 shares were traded during mid-day trading, a decline of 9% from the previous session's volume of 6,179 shares.The stock last traded at $8.39 and had previously closed at $8.65.
Analysts Set New Price Targets
PHAR has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer raised their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. Finally, Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company.
Get Our Latest Stock Analysis on PHAR
Pharming Group Stock Performance
The stock has a fifty day moving average price of $8.69 and a 200 day moving average price of $8.68. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a market cap of $531.66 million, a price-to-earnings ratio of -30.06 and a beta of -0.10.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, analysts predict that Pharming Group will post -0.2 earnings per share for the current year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
